Burney Co. cut its holdings in AstraZeneca plc (NYSE:AZN) by 12.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,269 shares of the company’s stock after selling 11,187 shares during the quarter. Burney Co.’s holdings in AstraZeneca were worth $3,286,000 as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in the company. TIAA CREF Investment Management LLC raised its position in AstraZeneca by 66.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 819,329 shares of the company’s stock worth $32,421,000 after purchasing an additional 326,817 shares during the last quarter. Capital Investment Advisory Services LLC bought a new position in AstraZeneca in the 4th quarter worth approximately $84,000. Pinnacle Associates Ltd. raised its position in AstraZeneca by 6.9% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,556 shares of the company’s stock worth $439,000 after purchasing an additional 748 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in AstraZeneca by 189.5% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,231,390 shares of the company’s stock worth $46,768,000 after purchasing an additional 805,985 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in AstraZeneca by 8.6% in the 4th quarter. Parallel Advisors LLC now owns 11,092 shares of the company’s stock worth $421,000 after purchasing an additional 876 shares during the last quarter. 18.79% of the stock is currently owned by hedge funds and other institutional investors.
AZN opened at $39.39 on Wednesday. The company has a debt-to-equity ratio of 1.48, a current ratio of 0.75 and a quick ratio of 0.58. AstraZeneca plc has a 52 week low of $34.38 and a 52 week high of $43.29. The firm has a market cap of $100.28 billion, a price-to-earnings ratio of 11.38, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47.
Several research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Thursday, April 4th. UBS Group cut shares of AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price objective for the company. in a research report on Tuesday, April 2nd. Cowen upgraded shares of AstraZeneca from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $42.00 to $48.00 in a research report on Monday, April 1st. ValuEngine cut shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Main First Bank restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, March 19th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. AstraZeneca presently has a consensus rating of “Hold” and a consensus target price of $45.29.
TRADEMARK VIOLATION WARNING: This piece was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://dakotafinancialnews.com/2019/06/12/burney-co-sells-11187-shares-of-astrazeneca-plc-nyseazn.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.